^
Association details:
Biomarker:RNF43 659
Cancer:Colorectal Cancer
Drug Class:PI3K inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition

Published date:
06/08/2022
Excerpt:
PI3K/mTOR inhibitors yield promising antitumor activity in RNF43659mut isogenic cell lines and xenograft models, as well as in patient-derived organoids harboring RNF43_p.G659fs mutations.
DOI:
10.1038/s41467-022-30794-7